Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
USWM CT, LLC
Study ID
NCT03391778
Phase
PHASE1
Status
Enrolling By Invitation

Conditions

  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • ADP adoptive cell therapy — BIOLOGICAL
    No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Study Details

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Key Dates

First listed
Jan 5, 2018
Start date
Apr 9, 2018
Status verified
Feb 2026
Primary completion
Apr 1, 2032
Completion
Apr 1, 2032

Study Design

Enrollment
250 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Participants receiving ADP adoptive cell therapy

Primary Outcome Measure

Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 15 years post last treatment ]

Locations (13)

Find similar trials in Atlanta, GA

Related Studies